Legal Opinion
In re Celexa & Lexapro Marketing & Sales Practices Litigation
District Court, D. Massachusetts
Decided February 5, 2013No. MDL No. 09-02067-NMGPublishedCited by 12 opinions
1Opinion of the Court
MEMORANDUM & ORDER
GORTON, District Judge.
This collection of lawsuits arises out of the marketing and sales of two related anti-depressant drugs by defendant Forest Pharmaceuticals (“Forest”), Celexa and Lexapro. The crux of the allegations is that from about 2001 to 2005, Forest illegally promoted the drugs for off-label use in pediatric and adolescent patients. The Food and Drug Administration (“FDA”) had, however, approved the drugs only for use in adult patients and, with respect to Celexa, the FDA had specifically denied approval for pediatric use. This Court rehearsed the facts…
2Cases cited18 opinions
- Klaxon Co. v. Stentor Electric Manufacturing Co.Supreme Court of the United States · 1941
- Amchem Products, Inc. v. WindsorSupreme Court of the United States · 1997
- General Telephone Co. of Southwest v. FalconSupreme Court of the United States · 1982
- In Re Tobacco II CasesCalifornia Supreme Court · 2009
- Mazza v. American Honda Motor Co., Inc.Court of Appeals for the Ninth Circuit · 2012
13 more not listed; retrieve them via the Exa API.
3Cited by12 opinions
- In Re: McCormick & Company, Inc., Pepper Products Marketing and Sales Practices LitigationDistrict Court, District of Columbia · 2016
- Painters & Allied Trades District Council 82 Health Care Fund v. Forest Laboratories, Inc.District Court, D. Massachusetts · 2014
- 4WEB, Inc. v. NuVasive, Inc.District Court, S.D. California · 2025
- Avery v. AKIMA Support Operations, LLCDistrict Court, E.D. California · 2022
- Ceron De Orozco v. Flagship Facility Services, Inc.District Court, S.D. California · 2020
7 more not listed; retrieve them via the Exa API.